Three-month treatment with monoclonal antibodies targeting the CGRP pathway is associated with multi-domain improvement of sensory processing and cortical network efficiency: results from a prospective case-control study
Abstract
Background/Hypothesis: Monoclonal antibodies targeting calcitonin gene-related peptide (CGRP mAbs) are effective drugs for migraine prevention. Worsening of symptoms following their discontinuation challenges their consideration as disease-modifying migraine drugs (DMMD). This study investigates whether changes in sensory processing and cortical network efficiency under CGRP mAb treatment. Methods: 22 patients suffering episodic migraine (21 female, 46.2+/-13.8 years) and 22 age-/gender-matched controls received visual and somatosensory evoked potentials (VEPs, SSEPs) assessments, and quantitative electroencephalography (qEEG). Patients were investigated before (V0),after three months (V3), and headache characteristics additionally followed-up at 6 and 12 months, of treatment with CGRP mAbs. Controls were assessed only once. Results: Facilitation of VEP at V0 in patients shifted to habituation at V3 following treatment with CGRP mAbs ({Delta}slope: -0.37+/-0.83, p=0.03). VEP habituation at V3 did not differ from controls. SSEPs were equally attenuated in patients and controls throughout the study. QEEG parameters in patients indicated impaired network efficiency at V0 that normalized at V3, and were unlike evoked potential studies correlated with six and twelve month outcomes. Conclusion/ Interpretation: Improved cortical network efficiency and sensory processing suggests disease-modifying effects of CGRP mAbs with delayed clinical effects on headache. Relapse after…
How strong is the evidence?
Evidence Hub reads this as a case-control. Its evidence level is 4 of 5 (Low · observational). Observational designs can show an association but not prove cause. Reported size: 22 participants or records.
Read the paper
Related studies
- Calcium Ions in the Physiology and Pathology of the Central Nervous System
- AI-powered in silico twins: redefining precision medicine through simulation, personalization, and predictive healthcare
- In silico functional, structural and pathogenicity analysis of missense single nucleotide polymorphisms in human MCM6 gene
- In Silico drug repurposing pipeline using deep learning and structure based approaches in epilepsy
- Targeting serotonin receptors with phytochemicals – an in-silico study
- In silico exploration of anti-prostate cancer compounds from differential expressed genes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.